Core Viewpoint - The company, Pharma Equity Group A/S, has published corrective information regarding its annual report for 2024 and interim report for H1 2025, following a decision from the Danish Business Authority that necessitated a reassessment of the receivable from Portinho S.A. using an Expected Credit Loss (ECL) model, resulting in significant write-downs of the receivable value [1][2][3]. Group 1: Background and Management's Statement - The Danish Business Authority issued a decision on November 20, 2025, requiring the company to reassess its receivable from Portinho S.A. using an ECL model as per IFRS 9 [2][3]. - The company has prepared a new valuation model that incorporates four probability-weighted outcomes: settlement, legal recovery, insolvency, and total loss [4]. - The Board of Directors and Executive Board have approved the supplementary information related to the annual and interim reports [7]. Group 2: Financial Corrections - The implementation of the ECL model has led to a significant write-down of the receivable as of December 31, 2024, and June 30, 2025, treated as an error correction under IAS 8 [5]. - The total cumulative effect of the correction as of December 31, 2024, is reflected in the annual financial statements for that year [5]. - The receivable from Portinho S.A. was originally valued at DKK 58 million, which has been adjusted to DKK 41.812 million following the correction [27][61]. Group 3: Financial Statements Impact - The updated consolidated income statement shows a loss for the year increasing from DKK 24.422 million to DKK 40.610 million due to the correction [26]. - The total assets have been adjusted from DKK 65.606 million to DKK 49.418 million, reflecting the write-down of the receivable [27]. - The equity has decreased from DKK 48.875 million to DKK 32.687 million as a result of the adjustments [27]. Group 4: ECL Model Details - The ECL model now reflects a probability-weighted approach with the following probabilities assigned: 45% for settlement, 30% for legal recovery, 20% for insolvency, and 5% for total loss [38][66]. - The reassessment of the receivable is considered a significant accounting estimate, with key sources of estimation uncertainty related to the recovery scenarios and probabilities assigned [39][50]. - The correction does not affect the company's legal claim against Portinho S.A. or the underlying contractual arrangements [35].

Core Viewpoint - Pharma Equity Group A/S has provided a strategic update indicating a significant adjustment in revenue and earnings expectations for the financial year 2025, shifting from an expected revenue of approximately DKK 11 million to no revenue, and increasing the pre-tax loss expectation from DKK 4-7 million to DKK 18-20 million, reflecting a strategic decision to prioritize long-term value creation over short-term gains [2][3]. Revenue and Earnings Expectations - The company has revised its revenue expectations for the financial year 2025 to zero, a significant change from the previously communicated expectation of DKK 11 million [2]. - The pre-tax loss expectation for the financial year 2025 has been adjusted to a range of DKK 18 to 20 million, up from the earlier estimate of DKK 4 to 7 million [3]. Strategic Decisions - The adjustments in revenue and earnings do not indicate a decline in the quality or potential of the underlying assets but are a result of a strategic choice to focus on long-term value creation rather than short-term agreements [3]. - The company has updated its Expected Credit Loss (ECL) model, which reflects a more conservative accounting practice but does not impact liquidity or strategic options for commercializing pipeline projects [4]. Pipeline Projects RNX-051 - Pharma Equity Group is engaged in advanced discussions with potential industrial partners regarding RNX-051, aiming to conclude these discussions in the first half of 2026 [5]. - The company has identified and addressed regulatory and operational barriers for international clinical studies with RNX-051, confirming that no material obstacles remain [8]. - The clinical study protocols for RNX-051 are in sub-final draft form and are expected to meet the requirements of potential licensing partners [7][9]. RNX-011 - Significant progress has been made in the development of RNX-011, with a clear strategy established for its continued advancement [11]. - The clinical study protocol for RNX-011 has been approved but will undergo targeted adjustments to enhance its design in line with partner expectations [12]. - Encouraging results have been previously demonstrated for RNX-011, and the company is focused on ensuring the study design supports its attractiveness for future licensing discussions [13]. Overall Strategy - The Board of Directors and Executive Management believe that the decision to forego short-term revenue is the most responsible approach for shareholder value creation [15]. - The company maintains a solid strategic foundation with a focus on maximizing long-term value through partnerships and licensing agreements [18].

Summary of Key Points from the Conference Call on China Banks Industry Overview - The focus is on the **Chinese banking sector**, particularly its exposure to the **property market** and the implications of projected property price declines on bank earnings and capital adequacy [1][2][3]. Core Insights and Arguments 1. **Property Price Forecast**: - The **GS China Property team** has revised its property price forecast, predicting a **15% decline** over the next two years, with a stress scenario of a **30% drop** [1][7][16]. - This decline is expected to impact mortgage and property non-performing loans (NPLs), with total mortgage and property NPLs estimated at **Rmb 2.3 trillion** under the base case and **Rmb 4.0 trillion** under the stress test [7][12]. 2. **Mortgage Exposure and Risk Profile**: - The total mortgage exposure in the banking system is **16%** of the loan book, with a healthy risk profile due to well-collateralized loans [1]. - The mortgage NPL ratio is projected to rise to **2.4%** by 2027, with covered banks at **2.1%** and non-covered banks at **3.4%** [8][12]. 3. **Earnings and Capital Risks**: - Earnings risks are anticipated, with a potential **6-22% haircut** on covered bank earnings through 2027, but banks are expected to remain profitable [2]. - In a severe scenario, risks of dividend cuts or capital calls may arise, particularly for smaller banks [2][43]. 4. **Dividend Outlook**: - Dividend yields are projected at **4-5%**, providing valuation support, with payouts expected to remain at **20-35%** for 2026 [3]. - Larger banks like **BOC** and **CCB** are favored for their robust balance sheets and total return potential [3]. 5. **Capital Buffers and Provisions**: - The banking sector has raised **Rmb 880 billion** in capital over the past three years, leading to a comfortable average Texas ratio of **18%** for covered banks [2][43]. - Under the base case, banks can absorb potential losses without creating a capital shortfall, but under the stress test, a cumulative capital shortfall of **Rmb 241 billion** is projected by 2027 [46][66]. 6. **Risk Management Strategies**: - Banks are advised to optimize balance sheets, reduce risk-weighted asset (RWA) density, and seek external capital replenishment to maintain stability [43][72]. - The full recourse nature of mortgages in China is expected to mitigate actual loss rates compared to potential NPL ratios [8][24]. Additional Important Insights - The decline in high-risk property credit exposures, such as property bonds and shadow banking, has improved the overall risk profile of banks [26]. - The number of city and rural banks in China has decreased, indicating a potential reduction in asset quality tail risks for small and medium-sized banks [78]. - The banking system's ability to maintain adequate NPL coverage and CET-1 ratios is crucial for navigating the anticipated property downturn [46][51]. This summary encapsulates the critical aspects of the conference call regarding the Chinese banking sector's outlook amidst property market challenges, highlighting both risks and strategies for resilience.

Core Viewpoint - The company, Pharma Equity Group A/S, is correcting its Annual Report for 2024 and Interim Report for H1 2025 following an order from the Danish Business Authority to apply an "Expected Credit Loss" (ECL) model for measuring receivables from Portinho S.A. [2][5] Summary by Sections Financial Consequences - The carrying amount of the receivable from Portinho S.A. as of December 31, 2024, is reduced from TDKK 58,000 to TDKK 41,812, resulting in a correction of TDKK 16,188 recognized in the income statement for 2024 [5][8] - For H1 2025, the fair value of the receivable is reassessed at TDKK 33,697, leading to a total negative correction of TDKK 24,303 in the balance sheet [9][10][14] Income Statement Adjustments - The operating profit/loss (EBIT) for 2024 remains at -21,287 TDKK, while the profit/loss for the year is adjusted from -24,422 TDKK to -40,610 TDKK due to the allowance for the Portinho receivable [8] - For H1 2025, the profit/loss for the year is adjusted from -9,495 TDKK to -17,610 TDKK, reflecting the correction of the allowance for the Portinho receivable [14] Auditor's Review and Future Steps - The company's auditor, BDO Statsautoriseret Revisionsaktieselskab, is reviewing the corrective information and will issue an auditor's report within approximately 14 days [3] - The company maintains its legal claim against the debtor and continues to pursue recovery through ongoing negotiations [11]